Showing results (231-240 of 318) with videos related to

Sort By:
Pageof 32
Harmful Algae|February 13, 2025
Cyanobacteria alter lipid metabolism in zooplankton via exudates of obesogensJinlong Zhang, Xuexiu Chang, Hugh J MacIsaac, et al.
The Medical Journal of Australia|September 16, 2014
The high burden of inpatient diabetes mellitus: the Melbourne Public Hospitals Diabetes Inpatient AuditLeon A Bach, Elif I Ekinci, Dennis Engler, et al.
British Journal of Anaesthesia|June 16, 2026
The effect of intraoperative dexamethasone on glycaemic responses in people with diabetes mellitus: a preplanned analysis of the Perioperative ADministration of Dexamethasone and Infection trialLeon A Bach, Catherine Martin, Richard J MacIsaac, et al.
Journal of Diabetes Investigation|November 30, 2021
Role of the adaptive immune system in diabetic kidney diseaseLingyun Kong, Sofianos Andrikopoulos, Richard J MacIsaac, et al.
The Science of the Total Environment|October 8, 2022
Identification of neurotoxic compounds in cyanobacteria exudate mixturesYuanyan Zi, Justin R Barker, Hugh J MacIsaac, et al.
Endocrinology, Diabetes & Metabolism|August 29, 2024
Utility of Adrenal Vein Sampling With and Without Ultra-Low Dose ACTH Infusion in the Diagnostic Evaluation of Primary AldosteronismChristopher A Preston, Eric X Z Yong, Benjamin Marginson, et al.
The Journal of Clinical Endocrinology and Metabolism|November 26, 2019
Effect of Salt Supplementation on Sympathetic Activity and Endothelial Function in Salt-Sensitive Type 2 DiabetesSara Baqar, Yee Wen Kong, Angela X Chen, et al.
Diabetes Care|July 10, 2013
Renal structure in normoalbuminuric and albuminuric patients with type 2 diabetes and impaired renal functionElif I Ekinci, George Jerums, Alison Skene, et al.
Diabetes Care|June 28, 2006
Is nonalbuminuric renal insufficiency in type 2 diabetes related to an increase in intrarenal vascular disease?Richard J MacIsaac, Sianna Panagiotopoulos, Karen J McNeil, et al.
Medicina (Kaunas, Lithuania)|May 27, 2026
The Emerging Role of Glucagon-like Peptide 1 (GLP-1)-Based Medications in the Treatment of Heart Failure, with a Focus on Heart Failure with Preserved or Mildly Reduced Ejection FractionRachel Su Min Lee, Jas-Mine Seah, Sara Baqar, et al.
Pageof 32